These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18564620)

  • 1. [Pharmacokinetic and pharmacodynamic features of palonosetron].
    Genazzani AA; Billington RA
    Tumori; 2008; 94(2):suppl 6-13. PubMed ID: 18564620
    [No Abstract]   [Full Text] [Related]  

  • 2. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann C; Herrstedt J
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):137-48. PubMed ID: 20131990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects].
    Pradelli L; Eandi M
    Tumori; 2008; 94(2):suppl 26-32. PubMed ID: 18564623
    [No Abstract]   [Full Text] [Related]  

  • 4. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
    Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
    [No Abstract]   [Full Text] [Related]  

  • 5. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist].
    Ajioka H; Morita F; Akizawa Y; Yoshida K; Kitamura R; Takimoto H
    Nihon Yakurigaku Zasshi; 2010 Aug; 136(2):113-20. PubMed ID: 20702972
    [No Abstract]   [Full Text] [Related]  

  • 7. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.
    Kuryshev YA; Brown AM; Wang L; Benedict CR; Rampe D
    J Pharmacol Exp Ther; 2000 Nov; 295(2):614-20. PubMed ID: 11046096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications.
    Blower PR
    Cancer J; 2002; 8(5):405-14. PubMed ID: 12416899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy].
    Di Maio M; Gallo C; Perrone F
    Tumori; 2008; 94(2):suppl 14-22. PubMed ID: 18564621
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
    Hamadani M; Awab A; Chaudhary L; Tfayli A
    J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
    [No Abstract]   [Full Text] [Related]  

  • 11. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.
    Rojas C; Thomas AG; Alt J; Stathis M; Zhang J; Rubenstein EB; Sebastiani S; Cantoreggi S; Slusher BS
    Eur J Pharmacol; 2010 Jan; 626(2-3):193-9. PubMed ID: 19836386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of dihydropyrimidine dehydrogenase from rat liver was not affected by any of five 5-hydroxytryptamine antagonists.
    Tateishi T; Nakura H; Watanabe M; Tanaka M; Kumai T; Kobayashi S
    Cancer Lett; 1996 Nov; 108(1):1-5. PubMed ID: 8950202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
    Shah AK; Hunt TL; Gallagher SC; Cullen MT
    Curr Med Res Opin; 2005 Apr; 21(4):595-601. PubMed ID: 15899109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.
    Hothersall JD; Moffat C; Connolly CN
    Br J Pharmacol; 2013 Jul; 169(6):1252-62. PubMed ID: 23581504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro.
    Behnam Motlagh P; Henriksson R; Grankvist K
    Acta Oncol; 1995; 34(6):871-5. PubMed ID: 7576757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
    Singh PM; Borle A; Gouda D; Makkar JK; Arora MK; Trikha A; Sinha A; Goudra B
    J Clin Anesth; 2016 Nov; 34():459-82. PubMed ID: 27687434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
    Navari RM
    Future Oncol; 2010 Jul; 6(7):1073-84. PubMed ID: 20624119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [From cocaine to innovative antiemetics. The medicinal chemistry of 5-ht3 receptor antagonists].
    Zettl H; Schubert-Zsilavecz M; Siebert CD
    Pharm Unserer Zeit; 2007; 36(5):354-61. PubMed ID: 17722162
    [No Abstract]   [Full Text] [Related]  

  • 20. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.
    Navari RM; Koeller JM
    Ann Pharmacother; 2003 Sep; 37(9):1276-86. PubMed ID: 12921512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.